ThermoStem™ Program (Brown Fat Stem Cells)

Potential Treatments for Preventing Type 2 Diabetes and Obesity

BRT’s ThermoStem™ Program is designed to develop treatments using brown fat stem cells for metabolic disorders and obesity focusing on potentially preventing the onset of Type 2 Diabetes. Additionally, we have identified the first stem cell population isolated from a particular brown adipose (fat) depot in humans.

Recent studies show that brown fat is present in the human body and has the ability to maintain and regulate metabolism. Potential use may include inducing weight loss (“biologic diet”) and the reduction of glucose and lipids – perhaps even leading to delaying or preventing the onset of Type 2 Diabetes.

As our brown fat cellular program advances, there is the opportunity to develop and collect data that may lead to the creation of a small molecule drug therapy (pharmaceutical) for the treatment of obesity and Type 2 Diabetes. 

Brown fat stem cells may have many other advantages and our ThermoStem™ Program plans on leveraging this groundbreaking research into different cellular therapies.

Brown Fat Advantages
Brown Fat Approach
Target Market
All of these advantages may have the potential to reduce the onset of, and risks relating to, Type 2 Diabetes and obesity.
•  Creates heat through thermogenesis, which increases caloric burning and induces weight loss
•  Dissolves or absorbs the bad "white fat,” which we are always trying to lose
•  Reduces glucose and lipid levels in the body — may prevent onset of Type 2 Diabetes or heart disease
•  Regulates metabolic homeostasis — balances metabolism
•  Fat to Fat (homologous) use of tissue – usually a safer and quicker path to treatment approval
The ThermoStem™ Program has taken a unique approach towards the use of brown fat by investigating three different pathways in developing therapies for its use :
•  Allogeneic – Brown fat stem cells that all people can use (off the shelf)
•  Autologous – Using your own stem cells, culturing them, then re-transplanting them
•  Small Molecule Drug – Pharmaceutical approach leading to conventional drug-based therapy
Obesity and diabetes are rampant throughout the United States. Below is a sample of just how widespread are these diseases. Search to see the most up to date statistics on these issues.
BRT’s ThermoStem™ Program may provide help to millions of people who are at risk for the onset of these diseases.
•  Prevalence: 25.8 million children and adults in the United States (8.3% of the population) have diabetes.
•  New Cases: 1.9 million new cases of diabetes were diagnosed in people aged 20 years and older in 2010
•  Projection: One study shows there will be 53.1 million Americans with diabetes by the year 2025.
•  Prevalence: In U.S., over 35% of the population was obese in 2009-2010.
•  New Cases: Obesity rates have grown steadily over the past decade and are expected to continue.
•  Projection: If the current trend continues, 50% of the population will be obese by 2030.
*All statistics taken from as of 4/27/12
BioRestorative Therapies: A Stem Cell Biotechnology Company